Skip to main content
VISIT JANSSEN GLOBAL
 
 
 

EMEA
change location▼

Search
Search
COVID-19 UPDATES >

Welcome to Janssen Europe, Middle-East and Africa

VISIT JANSSEN GLOBAL

Janssen EMEA › Media Center

Media Center

The Media Center is intented to provide resources for media professionals only. It is not inteded for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel

Press Releases

Oct 16, 2020

Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA®▼ (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union (EU)

Oct 16, 2020

Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV

Oct 15, 2020

New First-in-Class Phase 3 Data Demonstrate TREMFYA®▼ (guselkumab) Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis

Oct 13, 2020

Johnson & Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials

Oct 08, 2020

Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen’s COVID-19 Vaccine Candidate 

Sep 23, 2020

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate

View more Press Releases

Media Backgrounders

Neuroscience Backgrounder

Schizophrenia Backgrounder

Waldenström’s Macroglobulinemia (WM)

Stelara MOA infographic

The Role Of The Immune System In Crohn’s Disease

About Crohn’s Disease Backgrounder

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

 

Tweets

 

  • For Lisa, who lives with depression, frequent trips to the garden centre alleviated feelings of stress and anxiety.… https://t.co/9sj5IUbyyl

    14 hours 16 min ago

Follow us on Twitter
SUBSCRIBE TO OUR YOUTUBE CHANNEL